REDWOOD CITY, Calif. – Remote monitoring solutions provider Biotricity has completed the alpha version of Bioflux 2.0’s deep data diagnostic solution. The company intends to leverage its new artificial intelligence and deep data technology in arrhythmia analysis in its Bioflux 2.0 solution and focus on improved accuracy, faster diagnostics for patients, more efficient monitoring and improved call center efficiency. “We hope our deep data solution will eventually lead to near-instantaneous diagnostics, circumventing some of the current issues inherent in arrhythmia monitors, such as the delay that it takes for a physician to receive and analyze a patient report,” said Waqaas Al-Siddiq, founder and CEO of Biotricity, in a statement. “If we have the ability to anticipate a problem early we may have the potential to send preventative or predictive alerts.” Biotricity hopes to employ deep data science to increase the accuracy and efficiency of diagnostics with the first implementation in its Bioflux 2.0 solution.
You are here: / / Biotricity completes alpha deep diagnostic solution